Roche Venture Fund
Investor profile
Venture capital
Also recorded as: Roche Ventures
Deals
10
distinct rounds
Companies
8
backed
Active span
2013–2025
13 yrs
Total round €
€423M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Sofinnova Partners4
- 5AM Ventures2
- Novartis Venture Fund2
- Novo Holdings2
- Ysios Capital2
- AdBio partners1
- Agent Capital1
- Asabys Partners1
- Boehringer Ingelheim Venture Fund1
- Bristol Myers Squibb1
- Catalio Capital Management1
- Columbus Venture Partners1
- Draper Esprit1
- Eli lilly and company1
- EQT Life Sciences1
- Gilde Healthcare1
- HealthCap1
- INKEF Capital1
- IP Group1
- iSEED Ventures1
- JDRF T1D Fund1
- Jeito Capital1
- Kurma Partners1
- LifeArc Ventures1
- Lundbeck Foundation1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| GlycoEra | Switzerland | 2 | €157M |
| SpliceBio | Spain | 1 | €118M |
| Vivet Therapeutics | France | 1 | €38M |
| MISSION Therapeutics | UK | 2 | €35M |
| NMD Pharma | Denmark | 1 | €35M |
| DiogenX | France | 1 | €28M |
| Horizon Discovery | UK | 1 | €8.3M |
| MySugr | Austria | 1 | €4.4M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| SpliceBio | Series B | €118M | 2025-06 |
| GlycoEra | Series B | €114M | 2025-05 |
| GlycoEra | Series A | €43M | 2021-11 |
| Vivet Therapeutics | Series A | €38M | 2017-05 |
| NMD Pharma | Other | €35M | 2022-02 |
| DiogenX | Series A | €28M | 2023-05 |
| MISSION Therapeutics | Series B | €24M | 2013-10 |
| MISSION Therapeutics | Other | €11M | 2025-10 |
| Horizon Discovery | Series C | €8.3M | 2013-05 |
| MySugr | Series A | €4.4M | 2015-02 |